Zachary C Hartman

List of Publications by Year
in descending order

35 papers	1,841 citations	430874 18 h-index	477307 29 g-index
35 all docs	35 docs citations	35 times ranked	3512 citing authors

#	Article	IF	Citations
1	Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Therapy, 2023, 30, 794-802.	4.6	8
2	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. Molecular Cancer Therapeutics, 2022, 21, 217-226.	4.1	2
3	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight, 2022, 7, .	5.0	14
4	Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. , 2022, 10, e003721.		6
5	Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. Oncotarget, 2021, 12, 1-3.	1.8	2
6	Progesterone promotes immunomodulation and tumor development in the murine mammary gland. , 2021, 9, e001710.		12
7	HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. Molecular Cancer Research, 2021, 19, 1699-1711.	3.4	5
8	Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Research, 2021, 81, 4641-4651.	0.9	67
9	Abstract NG15: Progesterone-mediated immune evasion in breast cancer. , 2021, , .		0
10	How can we create precision immunotherapy as standard in breast cancer?. Expert Review of Anticancer Therapy, 2021, 21, 1179-1181.	2.4	0
11	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
12	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and Î±PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research, 2020, 26, 4670-4681.	7.0	31
13	IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils. Cancer Research, 2020, 80, 3088-3100.	0.9	14
14	HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression. , 2020, 8, e000258.		9
15	T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. Cell, 2019, 178, 1016-1028.e13.	28.9	150
16	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clinical Cancer Research, 2019, 25, 2725-2736.	7.0	50
17	Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. Clinical Cancer Research, 2019, 25, 9-11.	7.0	10
18	CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight, 2019, 4, .	5.0	77

#	Article	IF	Citations
19	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. OncoImmunology, 2018, 7, e1421891.	4.6	57
20	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research, 2018, 20, 90.	5.0	14
21	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. OncoImmunology, 2017, 6, e1264563.	4.6	23
22	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. OncoImmunology, 2017, 6, e1315495.	4.6	17
23	In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research, 2017, 23, 7531-7542.	7.0	15
24	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Cancer Immunology, Immunotherapy, 2017, 66, 1529-1544.	4.2	12
25	Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. Chemistry and Biology, 2013, 20, 1187-1197.	6.0	43
26	Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8. Cancer Research, 2013, 73, 3470-3480.	0.9	342
27	Increasing vaccine potency through exosome antigen targeting. Vaccine, 2011, 29, 9361-9367.	3.8	166
28	Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors. Molecular Cancer Therapeutics, 2011, 10, 1367-1374.	4.1	45
29	HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis. Cancer Research, 2011, 71, 4380-4391.	0.9	116
30	Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor Immunity. Cancer Research, 2010, 70, 7209-7220.	0.9	36
31	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity. Clinical Cancer Research, 2010, 16, 1466-1477.	7.0	24
32	Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology, 2008, 374, 453-467.	2.4	30
33	Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Research, 2008, 132, 1-14.	2.2	204
34	Adenovirus Infection Triggers a Rapid, MyD88-Regulated Transcriptome Response Critical to Acute-Phase and Adaptive Immune Responses In Vivo. Journal of Virology, 2007, 81, 1796-1812.	3.4	135
35	Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology, 2007, 358, 357-372.	2.4	77